<![CDATA[SOHO 2026: Disparities, Efficacy, and Long-Term Safety in B-Cell Lymphoma]]>

ConferenceCD20/CD3 bispecificNeutral

AI Analysis

Summary

SOHO 2026 conference featured posters examining sex-based differences in aggressive B-cell non-Hodgkin lymphoma, third-line therapies, and real-world safety data for CD20/CD3 bispecific therapeutics.

Importance:2/10

Sentiment:

0.00

B-cell lymphomaNHLsex-based disparitiesthird-line therapyreal-world safetyCD20/CD3 bispecificsSOHO 2026conference

Related Companies

$WHEN

Read the original article

Published by Cancer Network on September 18, 2026 2:00 PM

Read Original